AMOLYT PHARMA
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
AMOLYT PHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical Wellness
Founded:
2015-01-01
Address:
Écully, Rhone-Alpes, France
Country:
France
Website Url:
http://www.amolytpharma.com
Total Employee:
11+
Status:
Active
Contact:
33 428 01 21 54
Email Addresses:
[email protected]
Total Funding:
311.28 M USD
Technology used in webpage:
Bunny Fonts Constant Hosting
Similar Organizations
Cimeio Therapeutics
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Kinarus Therapeutics (SIX:KNRS)
Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
Osciflex
Osciflex system imitates nature’s process to prevent deadly blood clots.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series C - Amolyt Pharma
Tekla Capital Management
Tekla Capital Management investment in Series C - Amolyt Pharma
Sofinnova Partners
Sofinnova Partners investment in Series C - Amolyt Pharma
Credit Agricole Entreprises
Credit Agricole Entreprises investment in Series C - Amolyt Pharma
Pontifax
Pontifax investment in Series C - Amolyt Pharma
Intermediate Capital Group
Intermediate Capital Group investment in Series C - Amolyt Pharma
Bpifrance
Bpifrance investment in Series C - Amolyt Pharma
Sectoral Asset Management
Sectoral Asset Management investment in Series C - Amolyt Pharma
CTI Life Sciences Fund
CTI Life Sciences Fund investment in Series C - Amolyt Pharma
Kurma Partners
Kurma Partners investment in Series C - Amolyt Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-29 | Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.amolytpharma.com Semrush global rank: 8.39 M Semrush visits lastest month: 539
- Host name: amolytpharma.wpmudev.host
- IP address: 199.247.18.116
- Location: Frankfurt am Main Germany
- Latitude: 50.1103
- Longitude: 8.7147
- Timezone: Europe/Berlin
- Postal: 60314
More informations about "Amolyt Pharma"
Amolyt Pharma Enters into Definitive Agreement to be Acquired …
Disease, an organization with proven expertise and a successful track-record in bringing innovative therapies to patients with rare diseases globally.” Pierre Legault, hairman of Amolyt …See details»
Acquisition of Amolyt Pharma completed - AstraZeneca
Jul 15, 2024 AstraZeneca today announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel …See details»
AstraZeneca Closes Acquisition of Amolyt Pharma
AstraZeneca Closes Acquisition of Amolyt Pharma Lyon, France, and Cambridge, MA, July 15, 2024 — Amolyt Pharma, a global, clinical-stageSee details»
AstraZeneca to acquire Amolyt Pharma,
Mar 14, 2024 1. Clarke BL, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284-99.. 2. Vadiveloo, T, et al. A Population-based study of …See details»
Amolyt Pharma Enters into Definitive Agreement to be Acquired …
Mar 14, 2024 AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France …See details»
Amolyt Pharma Enters into Definitive Agreement to be Acquired …
Mar 14, 2024 Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its …See details»
Amolyt Pharma - Crunchbase Company Profile & Funding
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential …See details»
Novo Holdings Portfolio Company Amolyt Pharma Enters into …
Mar 14, 2024 /PRNewswire/ -- Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio company Amolyt Pharma ("Amolyt"), has...See details»
AstraZeneca Closes Acquisition of Amolyt Pharma - Markets Insider
Jul 15, 2024 LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializ...See details»
EQT Life Sciences portfolio company Amolyt Pharma to be …
Mar 14, 2024 Amsterdam, The Netherlands, March 14th, 2024 – EQT Life Sciences is pleased to announce that its portfolio company Amolyt Pharma has agreed to be acquired by Alexion, …See details»
Amolyt Pharma - LinkedIn
Amolyt Pharma | 9,042 followers on LinkedIn. Advancing peptides for the treatment of rare endocrine and related diseases | Amolyt Pharma is building on its team’s established expertise …See details»
Amolyt Pharma - EQT Group
Amolyt Pharma is a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseasesSee details»
AstraZeneca Closes Acquisition of Amolyt Pharma - GlobeNewswire
Jul 15, 2024 LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing …See details»
Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, …
Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and MetabolicSee details»
Amolyt Pharma Announces $138 Million Series C Financing led by ...
Jan 6, 2023 In September 2022, Amolyt presented positive efficacy and safety data from the first cohort of its Phase 2a study of eneboparatide at the American Society for Bone and Mineral …See details»
AstraZeneca - Research-Based BioPharmaceutical Company
Our company has continued on its strong growth trajectory in the first nine months of 2024. Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the …See details»
Amolyt Pharma Appoints Pierre Legault as a Director and …
Jun 8, 2020 LYON, France, and NEWTON, MA, June 8, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine …See details»
Amolyt Pharma Announces Abstracts Accepted for Presentation
May 16, 2022 LYON, France and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare …See details»
Microsoft Word - 2021-09-15 -- Amolyt -- $80M Financing
Sep 15, 2021 strong syndicate of international investors. To learn more, visit www.amolytpharma.com or follow us on Twitter at @AmolytPharma. At Amolyt: Media: …See details»
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on …
Jun 7, 2023 LYON, France, and Cambridge, MA, June 7, 2023 — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related …See details»